Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Cash Flow (2016 - 2025)

KalVista Pharmaceuticals' Net Cash Flow history spans 10 years, with the latest figure at -$39.0 million for Q2 2025.

  • For Q2 2025, Net Cash Flow fell 543.2% year-over-year to -$39.0 million; the TTM value through Apr 2025 reached -$29.8 million, down 28.1%, while the annual FY2025 figure was $97.8 million, 521.09% up from the prior year.
  • Net Cash Flow for Q2 2025 was -$39.0 million at KalVista Pharmaceuticals, down from $9.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $9.3 million in Q4 2024 and bottomed at -$39.0 million in Q2 2025.
  • The 3-year median for Net Cash Flow is -$58000.0 (2024), against an average of -$7.6 million.
  • The largest annual shift saw Net Cash Flow surged 99.16% in 2024 before it crashed 543.2% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at $8.9 million in 2023, then rose by 5.27% to $9.3 million in 2024, then plummeted by 518.54% to -$39.0 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Net Cash Flow are -$39.0 million (Q2 2025), $9.3 million (Q4 2024), and -$58000.0 (Q3 2024).